Quantitative Assessment of a Novel Device Designed for Patient-centric Sampling of Dried Plasma Using Targeted Proteomics
Year: 2025
Type: article
Abstract: High Resolution Image Download MS PowerPoint Slide Technological advancements have significantly enhanced proteomics by improving the quality, depth, and timeliness of proteomic data, making mass spectrometry a promising tool for personalized medicine. To enable successful longitudinal population-level monitoring, it is essential to have cost-efficient and convenient sample collection methods that yield reliable results. Microsampling performed by patients in their own homes fulfills this requirement. In this study, we evaluate a novel microsampling device that readily prepares a dried plasma sample from blood collected through a finger prick. The device was assessed quantitatively through a targeted proteomics approach, using a selection of stable isotope-labeled protein fragments as standards for plasma proteins spanning a range from 1300 μM to 30 nM. All samples were analyzed using selected reaction monitoring to ensure quantitative robustness. The device was assessed both from a storage perspective and across a group of healthy donors to ensure reliable performance between individuals. The dried plasma obtained from the device shows an excellent quantitative correlation with conventional plasma ( R > 0.99) and high quantitative precision, with a coefficient of variance (CV) below 10% for 80% of all peptides quantified in the group of healthy donors. All of the targets that perform well in the microsampling device also show good long-term stability when stored at room temperature for up to 232 days, further showcasing the potential benefits of collecting samples in a dry format.
Source: Analytical Chemistry
Institutions: AstraZeneca (United Kingdom), AstraZeneca (Sweden)
Language: English
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Funder: AstraZeneca
OpenAlex ID: W4411400778